261 related articles for article (PubMed ID: 31030250)
1. Implication of HMOX1 and CCR5 genotypes on clinical phenotype of Egyptian patients with sickle cell anemia.
Bakr S; Khorshied M; Talha N; Jaffer KY; Soliman N; Eid K; El-Ghamrawy M
Ann Hematol; 2019 Aug; 98(8):1805-1812. PubMed ID: 31030250
[TBL] [Abstract][Full Text] [Related]
2. Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, and GSTP1) in Egyptian pediatric patients with sickle cell disease.
Shiba HF; El-Ghamrawy MK; Shaheen IA; Ali RA; Mousa SM
Pediatr Dev Pathol; 2014; 17(4):265-70. PubMed ID: 24840051
[TBL] [Abstract][Full Text] [Related]
3. Association between BCL11A, HSB1L-MYB, and XmnI γG-158 (C/T) gene polymorphism and hemoglobin F level in Egyptian sickle cell disease patients.
El-Ghamrawy M; Yassa ME; Tousson AMS; El-Hady MA; Mikhaeil E; Mohamed NB; Khorshied MM
Ann Hematol; 2020 Oct; 99(10):2279-2288. PubMed ID: 32772141
[TBL] [Abstract][Full Text] [Related]
4. Significance of heme oxygenase-1(HMOX1) gene on fetal hemoglobin induction in sickle cell anemia patients.
Hariharan P; Chavan V; Nadkarni A
Sci Rep; 2020 Oct; 10(1):18506. PubMed ID: 33116199
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Impact of HMOX1 Polymorphism (rs2071746: A > T) in Indian Sickle Cell Disease Patients.
Pandey H; Singh K; Ranjan R; Dass J; Tyagi S; Seth T; Saxena R; Mahapatra M
J Lab Physicians; 2023 Dec; 15(4):583-589. PubMed ID: 37780888
[No Abstract] [Full Text] [Related]
6. Association of the
El Sissy MH; Hafez AA; Moneim SEA; Eldemerdash DM
Hemoglobin; 2019; 43(4-5):258-263. PubMed ID: 31657666
[TBL] [Abstract][Full Text] [Related]
7. Relation between glutathione S-transferase genes (GSTM1, GSTT1, and GSTP1) polymorphisms and clinical manifestations of sickle cell disease in Egyptian patients.
Ellithy HN; Yousri S; Shahin GH
Hematology; 2015 Dec; 20(10):598-606. PubMed ID: 25880856
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism in the HMOX1 gene is associated with high levels of fetal hemoglobin in Brazilian patients with sickle cell anemia.
Gil GP; Ananina G; Oliveira MB; Costa FF; Silva MJ; Santos MN; Bezerra MA; Hatzlhofer BL; Araujo AS; Melo MB
Hemoglobin; 2013; 37(4):315-24. PubMed ID: 23725037
[TBL] [Abstract][Full Text] [Related]
9. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
10. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
11. High frequency of the CCR5delta32 variant among individuals from an admixed Brazilian population with sickle cell anemia.
Chies JA; Hutz MH
Braz J Med Biol Res; 2003 Jan; 36(1):71-5. PubMed ID: 12532229
[TBL] [Abstract][Full Text] [Related]
12. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Green NS; Barral S
Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
[TBL] [Abstract][Full Text] [Related]
13. The Genetic and Clinical Significance of Fetal Hemoglobin Expression in Sickle Cell Disease.
Adekile A
Med Princ Pract; 2021; 30(3):201-211. PubMed ID: 32892201
[TBL] [Abstract][Full Text] [Related]
14. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
15. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
16. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
[TBL] [Abstract][Full Text] [Related]
17. The impact of MCP1-2518A/G and CCR2-V64I genetic polymorphisms in Egyptian sickle cell disease patients.
Ibrahim NS; Makhlouf MM; Shahin GH; Elghamrawy MK; Hussein NM
Exp Mol Pathol; 2022 Oct; 128():104834. PubMed ID: 36155203
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
19. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
[No Abstract] [Full Text] [Related]
20. Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.
Belini Junior E; Silva DG; Torres Lde S; Okumura JV; Lobo CL; Bonini-Domingos CR
Blood Cells Mol Dis; 2015 Apr; 54(4):321-7. PubMed ID: 25842370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
